Category - News

Markets

Ladenburg cuts Scynexis PT to $6 from $10

Ladenburg Thalmann lowered its price target for Scynexis (NASDAQ:SCNX) to $6 from $10, citing another delay in development of an IV formulation of ibrexafungerp. The stock closed at $1.39 on August 10. “As successful as...

August 13, 2018

Markets

JP Morgan starts Constellation Pharma at OW; PT $17

JP Morgan initiated coverage of Constellation Pharmaceuticals (NASDAQ:CNST) with an “overweight” rating and $17 December 2019 price target. The stock closed at $9.85 on August 10. Analyst Anupam Rama writes that using...

August 13, 2018

Markets

Leerink starts Crinetics Pharma at OP; PT $43

Leerink launched coverage of Crinetics Pharma (NASDAQ:CRNX) with an “outperform” rating and a $43 price target. The stock closed at $30.68 on August 10. Crinetics is building a rare disease franchise in endocrinology...

August 13, 2018

Markets

Piper cuts Endologix to neutral; PT $4.75 from $7, as Canaccord suspends coverage

Piper Jaffray downgraded Endologix (NASDAQ:ELGX) to “neutral” from “overweight” and lowered its price target to $4.75 from $7 after the company meaningfully reduced revenue guidance for the year as it moves to revamp...

August 10, 2018

Markets

Maxim ups BioLife Solutions PT to $26 from $18

Maxim Group hiked its price target for BioLife Solutions (NASDAQ:BLFS) to $26 from $18 as the company in the second quarter reported a net profit for the first time since inception. The stock was quoted at $19.68 in...

August 9, 2018

Markets

Ladenburg cuts Neovasc to neutral; PT to 8 cents

Ladenburg Thalmann downgraded Neovasc (NASDAQ:NVCN) to “neutral” from “buy” and slashed its price target to 8 cents from $1, reflecting reduced revenue projections coupled with a greatly increased number of shares...

August 9, 2018

Developments

electroCore in research pact with Mass General

electroCore (NASDAQ:ECOR) is collaborating with Massachusetts General Hospital (MGH) in a neuroinflammation research program. Under the program, electroCore’s non-invasive vagus nerve stimulation (nVNS) will be studied...

August 9, 2018

Markets

Stifel cuts Corindus Vascular Robotics to hold; PT $1

Stifel downgraded Corindus Vascular Robotics (NYSE AMER:CVRS) to “hold” from “buy” and slashed its price target to $1 from $3 after “disappointing” first half results and now-lower 2018-2020 sales projects. Shares of...

August 8, 2018

Developments

Growing dysphagia incidence driving development of alternative modes of drug delivery

A new study published in the peer-reviewed journal, Dysphagia, suggests that the proportion of seniors with swallowing problems in the U.S. is expected to top 20% by 2030 from 15% currently. “Dysphagia has...

August 7, 2018

Markets

WB ups Vital Therapies to OP and FVE to $35 from $10

William Blair upgraded Vital Therapies (NASDAQ:VTL) to “outperform” from “market perform” and raised its fair value estimate to $35 from $10 ahead of top-line data from a pivotal study expected in September. The stock...

August 6, 2018

Category - News

Subscribe